Question 1

Which TFF membranes are best for extracellular vesicle purification?

Accepted Answer

For extracellular vesicle (EV) purification, mPES TFF membranes with higher MWCOs (typically 100–300 kDa or above) are best suited because they provide high permeate flux and low fouling while effectively retaining vesicles such as exosomes and microvesicles. In automated systems like the µPulse and the aµtoPulse, controlled transmembrane pressure and gentle tangential flow preserve EV integrity while allowing smaller proteins and impurities to pass through. Selecting the right MWCO and membrane material improves EV recovery, shortens processing time, and delivers higher purity compared to centrifugation-based methods.

Question 2

Best TFF setup for lipid nanoparticle concentration?

Accepted Answer

For lipid nanoparticle (LNP) concentration, the most effective TFF setup uses a high-MWCO membrane with low non-specific binding and a controlled tangential flow configuration to preserve particle integrity while efficiently removing solvent and small impurities. In practice, this means selecting a regenerated cellulose (RC) membrane with an appropriate MWCO (often in the 300 kDa range) and operating at a moderate transmembrane pressure (TMP) that maintains steady flux without inducing shear stress. Automated systems like the µPulse and the aµtoPulse, with their precise TMP control, low hold-up volumes, and gentle microfluidic flow, support consistent, high-recovery concentration of LNPs. This configuration minimizes aggregation and membrane fouling while enabling reproducible buffer exchange or concentration in a single, walk-away run — making it ideal for formulation and process development of LNP-based therapeutics.

Question 3

Can a lab-scale TFF system be adapted for exosome isolation?

Accepted Answer

Yes, a lab-scale TFF system can be effectively adapted for exosome isolation. Systems like the µPulse and the aµtoPulse enable gentle, low-shear processing using high-MWCO membranes (typically ≥100–300 kDa) that retain exosomes while allowing smaller contaminants to pass through. The controlled transmembrane pressure, low hold-up volumes, and automated diafiltration improve exosome recovery, purity, and reproducibility compared to ultracentrifugation, making lab-scale TFF a practical and scalable approach for exosome processing.

Question 4

Can TFF concentrate lipid nanoparticles (LNPs) without aggregation?

Accepted Answer

Yes, TFF can concentrate lipid nanoparticles (LNPs) without aggregation when operated under controlled conditions. Using high-MWCO, low-binding membranes like RC and mPES with low, well-regulated transmembrane pressure (TMP) and gentle tangential flow prevents particle compaction and shear-induced aggregation. Automated lab-scale systems like the µPulse and the aµtoPulse provide precise TMP control, low hold-up volumes, and reproducible flow, enabling efficient LNP concentration and buffer exchange in a single run while preserving particle size, stability, and formulation quality.

Question 5

Which MWCO is best for siRNA or mRNA-loaded nanoparticles?

Accepted Answer

For siRNA- or mRNA-loaded nanoparticles, selecting the right MWCO is crucial to retain the particles while allowing smaller contaminants to pass. Typically, a 100 or 300 kDa MWCO membrane is recommended, as it efficiently retains lipid- or polymer-based nanoparticles in the 50–150 nm range without causing shear-induced damage. Using automated TFF systems like the µPulse or the aµtoPulse ensures controlled transmembrane pressure, gentle tangential flow, and low hold-up volume, minimizing aggregation and maximizing recovery while performing buffer exchange or concentration in a single run.

Question 6

How does TFF compare with centrifugation for nanoparticle recovery?

Accepted Answer

TFF offers several advantages over centrifugation for nanoparticle recovery. Unlike centrifugation, which relies on high g-forces and can cause aggregation, particle deformation, or sample loss, TFF uses gentle tangential flow across a membrane, preserving particle integrity while efficiently removing solvents and small impurities. Automated TFF systems like the µPulse and the aµtoPulse provide controlled transmembrane pressure, low hold-up volume, and reproducible recovery, enabling consistent concentration and buffer exchange of nanoparticles such as LNPs or exosomes. This results in higher recovery, reduced processing time, and minimal hands-on intervention compared to repeated centrifugation steps.

Question 7

What sample volumes can TFF handle for nanoparticle formulations?

Accepted Answer

TFF systems can handle a wide range of sample volumes for nanoparticle formulations. The µPulse efficiently processes 1–100 mL samples with a hold-up volume of 650 µL, making it ideal for lab-scale studies, while the aµtoPulse can process 0.5–100 mL per sample with a 250 µL hold-up volume and handle up to 54 samples per run in high-throughput workflows. These low hold-up volumes minimize material loss, making both systems suitable for precious or limited nanoparticle formulations while enabling efficient concentration and buffer exchange.

Question 8

Is TFF suitable for scaling nanoparticle production from research to GMP?

Accepted Answer

Yes, TFF is highly suitable for scaling nanoparticle production from research to GMP-compliant workflows. Systems like the µPulse allow precise small-volume processing for R&D, while the aµtoPulse supports high-throughput or pilot-scale runs with controlled transmembrane pressure, low hold-up volumes, and independent sample processing. This ensures consistent recovery, particle integrity, and reproducible buffer exchange across scales. Using TFF throughout development enables seamless translation from bench-scale experiments to GMP manufacturing, reducing process variability and facilitating regulatory compliance.

Question 9

How does TFF preserve nanoparticle size distribution and prevent aggregation during concentration?

Accepted Answer

TFF preserves nanoparticle size distribution and prevents aggregation by using gentle tangential flow across the membrane, which minimizes shear stress compared to centrifugation or normal flow filtration. Controlled transmembrane pressure (TMP) and flow in systems like the µPulse and the aµtoPulse maintain uniform permeate rates and low hold-up volumes, reducing dead zones where aggregation can occur. Additionally, selecting an appropriate MWCO membrane and maintaining compatible buffer conditions ensures that nanoparticles such as LNPs, exosomes, or viral vectors are concentrated efficiently while retaining their native size, structure, and functionality.

Question 10

What strategies can be used to maximize recovery of delicate nanoparticles such as exosomes or LNPs?

Accepted Answer

To maximize recovery of delicate nanoparticles such as exosomes or LNPs, it is important to use low-shear tangential flow with carefully controlled transmembrane pressure (TMP) to prevent aggregation and structural damage. Selecting the appropriate MWCO membrane (e.g. 300 kDa) ensures nanoparticles are retained while smaller impurities are removed. Systems with low hold-up volumes, such as the µPulse and the aµtoPulse, minimize dead zones and sample loss, while gentle buffer exchange conditions—including optimal pH, ionic strength, and temperature—preserve particle integrity. Additionally, using single-use chips or validated cleaning protocols prevents cross-contamination and supports reproducible recovery, resulting in high-yield, consistent nanoparticle concentration and diafiltration workflows.

Question 11

Can TFF be used for simultaneous nanoparticle concentration and buffer exchange (diafiltration)?

Accepted Answer

Yes, TFF can perform simultaneous nanoparticle concentration and buffer exchange (diafiltration) in a single run. Automated systems like the µPulse and the aµtoPulse use controlled tangential flow and transmembrane pressure to retain nanoparticles while continuously removing permeate and exchanging the buffer. This approach ensures high recovery, gentle handling, and reproducible results for sensitive particles such as exosomes, LNPs, or viral vectors, streamlining workflows by combining concentration and diafiltration without multiple manual steps.

Question 12

How does shear stress during TFF affect nanoparticle integrity, and how can it be minimized?

Accepted Answer

Shear stress during TFF can damage delicate nanoparticles, causing aggregation, deformation, or loss of functional integrity. To minimize shear, it is important to use low-shear tangential flow and operate at controlled transmembrane pressures (TMP). Automated systems like the µPulse and the aµtoPulse provide precise TMP control, gentle pulsatile flow, and low hold-up volumes, ensuring that nanoparticles such as exosomes, LNPs, or viral vectors are concentrated or diafiltered without compromising stability. Selecting appropriate MWCO membranes and maintaining compatible buffer and temperature conditions further preserves particle integrity during processing.

Question 13

Can TFF systems like µPulse or aµtoPulse handle heterogeneous nanoparticle populations in the same run?

Accepted Answer

Yes, TFF systems like the µPulse and the aµtoPulse can handle heterogeneous nanoparticle populations in the same run. By selecting an appropriate MWCO membrane and controlling transmembrane pressure and tangential flow rate, these systems retain nanoparticles across a defined size range while allowing smaller contaminants to pass. Features such as low hold-up volume, precise flow control, and gentle pulsatile pumping ensure that delicate particles—including exosomes, LNPs, and viral vectors—are recovered efficiently without aggregation or loss, making TFF suitable for complex formulations with mixed particle populations.

Question 14

How does membrane selection (RC vs. mPES) impact recovery and stability of lipid or polymeric nanoparticles?

Accepted Answer

Membrane selection significantly impacts the recovery and stability of lipid or polymeric nanoparticles during TFF. RC membranes are generally preferred for nanoparticles because they offer low non-specific binding, high flux, and chemical compatibility, minimizing particle loss and aggregation. mPES membranes may also be used but can exhibit slightly higher adsorption for certain lipid or polymeric formulations. Using automated systems like the µPulse and the aµtoPulse with the appropriate membrane ensures gentle tangential flow, controlled transmembrane pressure, and low hold-up volume, preserving nanoparticle integrity while maximizing recovery.

Question 15

What are the advantages of TFF over dialysis or chromatography for nanoparticle formulation?

Accepted Answer

TFF offers several advantages over dialysis or chromatography for nanoparticle formulation. Unlike dialysis, which relies on passive diffusion and can take hours to overnight, TFF actively removes solvents and small impurities through controlled tangential flow, enabling faster buffer exchange and concentration. Compared to chromatography, TFF offers scalability and eliminates the need for multiple equilibrations, while maintaining high recovery. Automated systems like the µPulse and the aµtoPulse provide precise transmembrane pressure, low hold-up volumes, and reproducible processing, allowing scalable, high-throughput workflows that combine concentration and diafiltration in a single run, reducing hands-on time and material loss.

Question 16

What are typical processing times for nanoparticle concentration and purification compared to centrifugation?

Accepted Answer

TFF significantly reduces processing times for nanoparticle concentration and purification compared to centrifugation. While centrifugation often requires multiple spins with intermediate handling, taking hours, TFF systems like the µPulse and the aµtoPulse complete concentration and buffer exchange in minutes per sample. Controlled tangential flow and transmembrane pressure enable continuous removal of permeate while retaining nanoparticles, providing gentle, high-recovery processing with minimal hands-on intervention. This results in faster, more reproducible workflows for sensitive nanoparticles such as LNPs, exosomes, or viral vectors.

Small-Molecule Crystallization

Small-Molecule Crystallization Workflow

Need for Automation

Automation Solutions by Formulatrix

Formulator^® - Screen Builder

NT8^® - Drop Setter

Rock Imager^® - Crystallization Imager

Rock Maker^® - Crystallization Software

Prof. Dr. Bernhard Spingler

Titularprofessor

Webinars

Crystallization of Small-Molecules with Robotic Methods

Products

Resources

Discover

Contact